Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fixed-Dose Combination · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Fixed-Dose Combination (FDC) Tablet | DRUG | Obicetrapib/Ezetimibe FDC tablet |
The Fixed-Dose Combination is an investigational small molecule being studied in healthy volunteers. It is being evaluated in a Phase 1 clinical trial to investigate the effect of food on its bioavailability. The drug combines obicetrapib and ezetimibe in a single fixed-dose formulation.
NewAmsterdam Pharma Company N.V. (ticker: NAMS) is developing the Fixed-Dose Combination. The company is conducting a Phase 1 clinical trial of this investigational drug, which combines obicetrapib and ezetimibe, in healthy volunteers.
The Fixed-Dose Combination is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed, with no active trials currently ongoing.
The Fixed-Dose Combination has one completed Phase 1 trial, NCT06050291, titled "Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe." This trial enrolled 28 healthy volunteers and was uncontrolled, meaning it did not use a comparator group.
The Fixed-Dose Combination is a single formulation that contains both obicetrapib and ezetimibe. It is being studied to assess how food affects the bioavailability of this combined product, as opposed to the individual components taken separately.